29-APR-2025 6:10

Lung-MAP ACCRUAL REPORT

  O
P
E
N		 ACCR
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
LUNGMAP Screening Protocol Registrations
Total     3619 267 98 62 23 8 02/06/2019 425 183
Screened at PD     1262 63 28 18 6 1      
Pre-Screened prior to PD     2354 201 67 41 14 6      
Treatment-naive     3 3 3 3 3 1      
ctDNA Specimen Submission     315 0 0 0 0 0      
Re-analysis Requests     503 64 10 7 3 0      
 
Sub-Study Assignments
LUNGMAP Sub-Study Assignments     1765 49 16 10 5 2      
Screened at PD     998 25 11 7 2 1      
Pre-Screened prior to PD     712 21 2 0 0 0      
Treatment-naive     3 3 3 3 3 1      
After PD on a Lung_MAP Sub-Study     52 0 0 0 0 0      
 
Sub-Study Assignments (open studies only)
S1900G     29 12 4 2 1 0      
S1900J     11 11 3 3 0 0      
S1900K     13 11 7 5 4 2      
 
Sub-Study Registrations
LUNGMAP Sub-Study Registrations     501 22 10 6 5 1      
Initial sub-study registrations     489 22 10 6 5 1      
Subsequent sub-study registrations     12 0 0 0 0 0      
 
Patients Registered to a Sub-Study (open studies only)
S1900G: EGFR-Mut, MET-Amp: Capmat + Osimert +/- Ramu   66 19 8 3 2 1 0 05/05/2023 272 103
Capmatinib + Osimertinib + Ramucirumab Y   10 6 3 2 1 0      
Capmatinib + Osimertinib Y   9 2 0 0 0 0      
S1900J: MET Amplification: Amivantamab-SC   88 2 2 2 1 1 0 11/19/2024 178 72
Amivantamab SC Y   2 2 2 1 1 0      
S1900K: MET Exon 14: Tepotinib +/- Ramucirumab   56 6 6 4 3 3 1 08/08/2024 249 84
Tepotinib + Ramucirumab Y   4 4 3 2 2 1      
Tepotinib Y   2 2 1 1 1 0      
 

29-APR-2025 6:10

Lung-MAP Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
S1800E Non-Match: Docetaxel + Ramu +/- Cemiplimab 1 Randomization 28-Apr-25 105 31